Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
09:07am, Friday, 08'th Nov 2024
Bagsværd, Denmark, 8 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated p
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
12:27pm, Thursday, 07'th Nov 2024
Bagsværd, Denmark, 7 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated p
Novo Nordisk CEO on earnings: Very bullish on 2025 despite demand concerns
12:02pm, Thursday, 07'th Nov 2024
Lars Fruergaard Jørgensen, Novo Nordisk CEO, joins 'Money Movers' to discuss Jorgensen's comments on demand in 2025, if demand is waning for GLP-1 drugs, and much more.
These 3 Stocks Are Winning Thanks to Baby Boomers
11:12am, Thursday, 07'th Nov 2024
According to a March 2023 study from the Bank of America Institute about consumer spending, seniors born in 1964 or earlier were the only age cohort in the U.S.
Novo Nordisk expects high demand for its obesity drugs in India, says country head
01:10pm, Wednesday, 06'th Nov 2024
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when launched in India, a top executive said.
NVO Misses Q3 Earnings & Revenue Estimates, Updates 2024 View
12:51pm, Wednesday, 06'th Nov 2024
Novo Nordisk reports lower-than-expected Q3 results, missing both earnings and revenue estimates. Management updates 2024 financial guidance.
Novo Nordisk A/S (NVO) Q3 2024 Earnings Call Transcript
11:48am, Wednesday, 06'th Nov 2024
Novo Nordisk A/S (NVO) Q3 2024 Earnings Conference Call November 6, 2024 7:00 AM ET Company Participants Jacob Martin Wiborg Rode - Head of Investor Relations Lars Fruergaard Jorgensen - President and
Novo Nordisk Stock Slips as Sales Grow Less Than Expected
10:36am, Wednesday, 06'th Nov 2024
After rising in premarket trading, Novo Nordisk's (NVO) U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of estimates despite continued growth form weigh
Novo Nordisk CFO says 2025 sales could see high-teens percentage growth
08:40am, Wednesday, 06'th Nov 2024
Novo Nordisk's sales growth next year could be in the high teens in percentage terms, Chief Financial Officer Karsten Munk Knudsen said on an analyst call following the release of third-quarter earnin
Novo Nordisk Stock Rises on Earnings Beat, Narrowed Outlook
08:20am, Wednesday, 06'th Nov 2024
Novo Nordisk's (NVO) U.S.-listed shares rose Wednesday morning as it reported better third-quarter profits than expected, though sales of its drugs including popular weight-loss treatments Ozempic and
Novo Nordisk CEO on Wegovy prices, supplies and compounding
07:43am, Wednesday, 06'th Nov 2024
Novo Nordisk reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its shares up nearly 9%.
Ozempic maker Novo Nordisk nudges higher profit forecast
07:24am, Wednesday, 06'th Nov 2024
Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.
Novo Nordisk says its experimental drug CagriSema has similar side effects to Wegovy
05:54am, Wednesday, 06'th Nov 2024
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection
Novo Nordisk lifts curbs on Wegovy prescriptions in the U.S., says CEO
05:31am, Wednesday, 06'th Nov 2024
Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.
